News Summary:
On July 31, 2026, Maryland Attorney General Anthony Brown announced settlements totaling over $13 million with seven opioid drug manufacturers, including Alvogen. This multistate settlement resolves allegations that the companies' manufacturing, marketing, and sales practices contributed to the widespread diversion of prescription opioids such as oxycodone, hydrocodone, and fentanyl patches. Previously, on June 26, 2026, the U.S. Food and Drug Administration (FDA) approved the first generic single-dose oral formulation of Xofluza (baloxavir marboxil) tablets for influenza in individuals aged five years and over. Norwich Pharmaceuticals, identified as Alvogen's manufacturing and research hub, received this authorization, marking an advancement in treatment and prophylaxis of acute uncomplicated influenza. Earlier, on June 18, 2026, Petar Vazharov, CEO of Lotus Pharmaceuticals, was highlighted for his career trajectory, having joined Alvogen in 2009 as one of its initial international hires, building its Central and Eastern European business before leading Lotus Pharmaceutical’s expansion and growth. On June 17, 2026, the FDA approved Alvogen's Abbreviated New Drug Application (ANDA) 208269 for a 20mg extended-release Hydrocodone Bitartrate tablet.
Subscribe for full access to Alvogen's profile
Subscribe for full access to Alvogen's products in full detail 
